We use cookies to enhance your browsing experience, analyze website traffic, and maintain essential site functionality. By clicking "Accept All", you consent to our use of cookies. For more details, please review our Privacy Policy.

NuCana Stock (NASDAQ:NCNA)


Chart

Previous Close

$0.06

52W Range

$0.03 - $10.79

50D Avg

$0.20

200D Avg

$1.10

Market Cap

$342.22K

Avg Vol (3M)

$151.99M

Beta

1.25

Div Yield

-

NCNA Company Profile


NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

GB

Employees

20

IPO Date

Sep 28, 2017

Website

NCNA Performance


Total Return %
1D
5D
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
NCNA
S&P 500
-6.61%
-31.93%
-5.52%
-93.35%
-95.69%
-95.44%
-97.95%
-99.66%
-99.96%
-99.99%
0.45%
1.24%
4.09%
15.60%
4.81%
6.13%
12.51%
62.44%
95.69%
200.14%

Peer Comparison


TickerCompany
CDTXCidara Therapeutics, Inc.
TLPHTalphera, Inc.
GLYCGlycoMimetics, Inc.
IFRXInflaRx N.V.
PRQRProQR Therapeutics N.V.
SONNSonnet BioTherapeutics Holdings, Inc.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools